Abstract

It has been found that by generating multiple nicks in the DNA region proximal to a specific site of homologous chromosomes, DNA exceeding 100 bp can be deleted in one of the homologous chromosomes.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

A compound represented by formula [I]: A compound represented by formula [I]: A compound represented by formula [I]: wherein R12, R13, R14, R15, and R16 are the same or different and are each hydrogen, halogen, C1-6 alkyl optionally substituted with halogen, or C1-6 alkoxy optionally substituted with halogen; R21, R22, and R23 are the same or different and are each hydrogen, halogen, C1-6 alkyl optionally substituted with halogen, C1-6 alkoxy optionally substituted with halogen, sulfanyl optionally substituted with halogen, nitro, or cyano; R3 is C1-6 alkyl or the like; and X− is an anion.

IPC Classes  ?

• C07D 219/04 - Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
• B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
• B01J 35/39 - Photocatalytic properties
• C07C 37/60 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by oxidation reactions introducing directly a hydroxy group on a CH-group belonging to a six-membered aromatic ring with the aid of other oxidants than molecular oxygen or their mixtures with molecular oxygen

Abstract

A method for manufacturing a Group III nitride crystal, the method including: bringing a surface of a Group III nitride seed crystal into contact with a melt including at least one Group III element selected from among gallium, aluminum, and indium and an alkali metal in an atmosphere containing nitrogen to cause the Group III element and the nitrogen to react with each other in the melt to grow a Group III nitride crystal on the Group III nitride seed crystal, the method includes: growing a plurality of island-like Group III nitride crystal nuclei on the surface of the Group III nitride seed crystal; growing a first Group III nitride crystal having an inverted triangular shape or a trapezoidal shape in section from each of the plurality of island-like Group III nitride crystal nuclei; and growing a second Group III nitride crystal such that the second Group III nitride crystal fills a depression of the first Group III nitride crystal to form the second Group III nitride crystal having a flat surface, wherein in the course of growing the plurality of island-like Group III nitride crystal nuclei, a temperature is set to 875° C. or more and a nucleation density is set to 1*106/cm2 or less, and in the course of growing the first Group III nitride crystal and growing the second Group III nitride crystal, immersion of the Group III nitride seed crystal in the melt and pulling up from the melt are repeated a plurality of times.

IPC Classes  ?

• C30B 25/20 - Epitaxial-layer growth characterised by the substrate the substrate being of the same materials as the epitaxial layer
• C30B 29/40 - AIIIBV compounds
• C30B 29/66 - Crystals of complex geometrical shape, e.g. tubes, cylinders

Abstract

As one embodiment, the present application discloses a divalent molecule that can bind to both natural AAV capsid and a molecular target. As another embodiment, a method by which high gene transfer efficiency can be achieved in a receptor-dependent manner by using, as a vector, a complex with natural AAV capsid formed using the molecule as an engager is also disclosed. These embodiments contribute to simultaneously achieving two purposes: using natural AAV capsid that has not been modified at all, and dramatically increasing infectivity to target cells. These embodiments are useful, for example, in the field of gene therapy and the like.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• C07K 7/50 - Cyclic peptides containing at least one abnormal peptide link
• C07K 14/015 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/864 - Parvoviral vectors

Abstract

Provided is a luminescent protein that emits light at high light intensity in a plurality of wavelength regions.　The luminescent protein comprises a complex of a bacterial luciferase and a fluorescent protein, wherein the bacterial luciferase has a LuxA subunit and a LuxB subunit, and the fluorescent protein is fused with the bacterial luciferase via the LuxA subunit.

IPC Classes  ?

• C07K 19/00 - Hybrid peptides
• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/53 - Oxidoreductases (1)
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 21/00 - Preparation of peptides or proteins
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase

Abstract

It is provided that a laminated body having high adhesiveness between a resin layer and a metal layer without roughening the surface of the resin layer or the metal layer or providing an intermediate layer between the resin layer and the metal layer. A laminated body comprising a resin layer and a metal layer, wherein the metal layer is stacked directly on a surface of the resin layer containing a fluorine-based resin, an adhesive strength between the resin layer and the metal layer is 0.7 N/mm or higher, and the metal layer has a surface roughness Sq of 0.2 μm or smaller.

IPC Classes  ?

• B32B 15/08 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin
• B32B 15/20 - Layered products essentially comprising metal comprising aluminium or copper
• B32B 37/00 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding
• B32B 37/06 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the heating method
• B32B 37/10 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the pressing technique, e.g. using direct action of vacuum or fluid pressure
• B32B 37/18 - Methods or apparatus for laminating, e.g. by curing or by ultrasonic bonding characterised by the properties of the layers with all layers existing as coherent layers before laminating involving the assembly of discrete sheets or panels only
• B32B 38/00 - Ancillary operations in connection with laminating processes

Abstract

A brain function improving agent prevents the onset of, treats, and/or ameliorates cognitive function impairment and depressive symptoms in central nervous system diseases. The agent contains as active ingredient, at least one among 5-(3,5-dihydroxyphenyl)-γ-valerolactone represented by formula (I), a salt of said compound, and a conjugate of said compound.

IPC Classes  ?

• A61K 31/365 - Lactones

Abstract

Provided is a plating film that has excellent heat resistance and thermal shock resistance and that is suitable for metal sintering bonding.　The plating film for metal sintering bonding has (A) an electroless nickel-phosphorus plating film, and is characterized in that the phosphorus content of the electroless nickel-phosphorus plating film (A) is 4 mass% or less with respect to 100 mass% of the electroless nickel-phosphorus plating film.

IPC Classes  ?

• C23C 18/36 - Coating with one of iron, cobalt or nickelCoating with mixtures of phosphorus or boron with one of these metals using reducing agents using hypophosphites
• C23C 18/42 - Coating with noble metals
• C23C 18/52 - Chemical coating by decomposition of either liquid compounds or solutions of the coating forming compounds, without leaving reaction products of surface material in the coatingContact plating by reduction or substitution, i.e. electroless plating using reducing agents for coating with metallic material not provided for in a single one of groups
• H01L 23/12 - Mountings, e.g. non-detachable insulating substrates

Abstract

A spectrometry apparatus (1) according to the present embodiment includes a light source (11) that produces illumination light, a spectrophotometer (50) that disperses signal light rays from a sample illuminated with the illumination light and detects the signal light rays by a photodetector (55), a fiber unit (40) having a plurality of fibers, the plurality of fibers (45) being adjacently arranged at an entrance end surface (411) of the fiber unit (40), and the plurality of fibers (45) being arranged in a multi-line shape at intervals at an exit end surface, and a processing unit that, by referring to a positional relationship among the plurality of fibers (45) at the entrance end surface and an exit end surface of the fiber unit (40), generates a spectroscopic image of the sample S from a result of detection by the photodetector.

IPC Classes  ?

• G01J 3/02 - SpectrometrySpectrophotometryMonochromatorsMeasuring colours Details
• G01J 3/44 - Raman spectrometryScattering spectrometry
• G01N 21/65 - Raman scattering

Abstract

The present invention provides: a positive electrode active material for lithium sulfur batteries, which contains a sulfur polymer that can be synthesized at a lower temperature than ever before; a positive electrode material; a positive electrode; and a lithium sulfur battery.　The present invention provides a positive electrode active material for lithium sulfur batteries, which contains a sulfur-containing polymer compound, the sulfur-containing polymer compound having a structural unit that is represented by general formula (1) -R1-R-R1nn- or the like. (In formula (1), n represents a number of 1 or more, R represents an organic group, and R 1 represents a divalent organic group that is derived from a polycondensable functional group.)

IPC Classes  ?

• H01M 4/60 - Selection of substances as active materials, active masses, active liquids of organic compounds
• H01M 4/137 - Electrodes based on electro-active polymers
• H01M 10/052 - Li-accumulators
• H01M 10/0562 - Solid materials
• H01M 10/0566 - Liquid materials

Abstract

Provided are: an antibody selection method, a computer program, and an information processing device.　An antibody that exhibits specificity for a prescribed antigen is selected by: acquiring sequence data for a plurality of antibodies that includes an antibody for which the antigen specificity is unknown; clustering the acquired sequence data for the plurality of antibodies from the standpoint of similarity of a paratope pseudosequence; discriminating a cluster that exhibits specificity for the prescribed antigen by using a subset of the antibodies in each cluster; and estimating that, within a discriminated cluster, the antibody outside the subset has the same antigen specificity as the antibody in the subset.

IPC Classes  ?

• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C12N 15/13 - Immunoglobulins
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor

Abstract

[Problem] To provide a plasma-assisted polishing method and a device therefor, capable of suppressing one-sided wear of a polishing pad and facilitating attachment/detachment work of a polishing pad and a workpiece in processing of a hard-to-work material using a plasma-assisted polishing method. [Solution] In an operation for relatively moving a workpiece W and a polishing pad P, the workpiece is polished by a combination of the rotation of the workpiece and the polishing pad each having an axis in a first direction, and the swing in a second direction orthogonal to the first direction and increasing or decreasing the distance between the two axes. The workpiece and the polishing pad face each other by being detachably held by mounting parts 10, 13 provided with rotary shafts 9, 12 each directed in the first direction. When the workpiece and/or the polishing pad is attached/detached, the workpiece and the polishing pad are moved in the second direction beyond a range of oscillation in a normal polishing process in a state of stopping the rotation of the workpiece and/or the polishing pad, and the workpiece and/or the polishing pad is attached/detached to/from the mounting part in a state where the workpiece and/or the polishing pad is exposed from the facing member.

IPC Classes  ?

• B24B 1/00 - Processes of grinding or polishingUse of auxiliary equipment in connection with such processes
• B24D 3/00 - Physical features of abrasive bodies, or sheets, e.g. abrasive surfaces of special natureAbrasive bodies or sheets characterised by their constituents
• B24D 3/14 - Physical features of abrasive bodies, or sheets, e.g. abrasive surfaces of special natureAbrasive bodies or sheets characterised by their constituents the constituent being used as bonding agent and being essentially inorganic ceramic, i.e. vitrified bondings
• B24D 7/00 - Bonded abrasive wheels, or wheels with inserted abrasive blocks, designed for acting otherwise than only by their periphery, e.g. by the front faceBushings or mountings therefor
• H01L 21/304 - Mechanical treatment, e.g. grinding, polishing, cutting

Abstract

The present disclosure relates to a semiconductor nanoparticle composite film including semiconductor nanoparticles and diamond-like carbon (DLC), the composite film satisfying at least one selected from the group consisting of: i) the composite film includes mainly the semiconductor nanoparticles; and ii) at least a portion of the semiconductor nanoparticles are arranged in line. The composite film can be obtained by, for example, irradiating a semiconductor nanoparticle-containing film including semiconductor nanoparticles and a carbon source with an ion beam to generate DLC. The carbon source includes an organic compound other than a polymer.

IPC Classes  ?

• C01B 32/05 - Preparation or purification of carbon not covered by groups , , ,
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• C01G 3/12 - Sulfides

Abstract

The present invention provides a computer program or the like, capable of improving the utilization degree of a detection signal detected by using an optical sensor.　A computer program according to one aspect of the present disclosure causes a computer to execute processing for: acquiring a first profile indicating a change in interaction between substances detected by using an optical sensor; Fourier-transforming the acquired first profile to acquire a spectrum for each frequency; inverse-Fourier-transforming the spectrum of a specific frequency among the acquired spectra for the respective frequencies to generate a second profile; and acquiring a classification of a group to which the second profile belongs when the second profile has been classified into a plurality of groups.

IPC Classes  ?

• G01N 21/41 - RefractivityPhase-affecting properties, e.g. optical path length
• G01N 21/45 - RefractivityPhase-affecting properties, e.g. optical path length using interferometric methodsRefractivityPhase-affecting properties, e.g. optical path length using Schlieren methods

Abstract

Provided are an information processing method, a learning model generation method, a learning model, a computer program, and an information processing device.　In the present invention, a computer executes processing wherein: data of an adaptive immune receptor of a subject is acquired; a calculation based on the acquired data of the adaptive immune receptor of the subject is executed using a learning model trained to output information on a disease estimated from an adaptive immune receptor on the basis of data of the adaptive immune receptor; and information on a disease inferred from the adaptive immune receptor of the subject on the basis of the calculation result executed using the learning model is output.

IPC Classes  ?

• G16B 40/20 - Supervised data analysis

Abstract

This state estimation device estimates a state of each point of a partial point group, which is a finite part of a point group structure in which one or more types of points spread infinitely through a space, by using, as input, a type and position of each point of the partial point group. The state estimation device includes: an acquisition unit that acquires a type and position of an input point as input information; and a state estimation unit that estimates a feature vector corresponding to the input information by a state estimation model that is a trained model obtained by machine learning a correspondence relationship between the type and position of a point in the partial point group and a feature vector representing a state of each point of the partial point group.

IPC Classes  ?

• G06N 3/08 - Learning methods
• G06F 17/14 - Fourier, Walsh or analogous domain transformations
• G06N 3/0475 - Generative networks

Abstract

Provided are a method for manufacturing a three-dimensional-shaped article and an ink set for production of a three-dimensional-shaped article which make it possible to manufacture a three-dimensional-shaped article with good shaping precision, even when manufacturing a three-dimensional-shaped article that has a complex shape and that is made from a soft material, for example. The present invention relates to a method for manufacturing a three-dimensional-shaped article, said method comprising: a step for respectively discharging (a) a model material ink which contains an ion-crosslinkable polymer and (b) a support material ink which contains a support material and a crosslinking factor; a step for curing the discharged ion-crosslinkable polymer; and a step for removing a shaped article of the support material ink.

IPC Classes  ?

• B29C 64/106 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material
• B29C 64/40 - Structures for supporting 3D objects during manufacture and intended to be sacrificed after completion thereof
• B33Y 70/00 - Materials specially adapted for additive manufacturing

Abstract

[Problem] The problem addressed is to discover clinically useable non-invasive index that makes it possible to predict the effect of combination therapy by multiple drugs, including immune checkpoint inhibitors, in hepatocellular carcinoma. [Solution] Using the peripheral blood of a hepatocellular carcinoma patient as a sample, the effect of combination therapy by multiple drugs, including immune checkpoint inhibitors, is predicted by a test method that includes at least one of steps (a)-(d). For example, the effect of combination therapy by an immune checkpoint inhibitor and an angiogenesis inhibitor is predicted. Preferably, the method includes a step for comparing the measured value with a reference value. (a) A step for measuring the relative cell count of CD14+ cells, (b) a step for measuring the expression level of a gene such as FABP5 in CD14+ cells, (c) a step for measuring the relative cell count of CD4+ cells that are positive for CCR7, etc., (d) a step for measuring the expression level of a gene such as FOS in CD4+ cells.

IPC Classes  ?

• C12Q 1/6869 - Methods for sequencing
• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

According to this welded joint, welded structure, and welding method, a welded joint formed between steel plates of which the ends are butted against each other comprises a first welding layer and a second welding layer that is stacked on the first welding layer and is adjacent to the surface of the steel plates. The first welding layer has arrestability for suppressing propagation of brittle cracks, and the second welding layer has SCC resistance for suppressing stress corrosion cracking (SCC) caused by a fluid in contact with the surface of the steel plates.

IPC Classes  ?

• B23K 31/00 - Processes relevant to this subclass, specially adapted for particular articles or purposes, but not covered by any single one of main groups
• B23K 9/00 - Arc welding or cutting
• B23K 9/095 - Monitoring or automatic control of welding parameters

Abstract

A computer-readable recording medium storing therein a program for causing a computer to execute a process including: obtaining constraint conditions forming a 0-1 integer programming problem including variables each taking a value 0 or 1, each constraint condition including at least one of the variables; identifying pairings of a variable appearing only in a predetermined number of constraint conditions and the constraint conditions where the variable appears, the predetermined number being less than a total number of the constraint conditions; registering, in a storage unit, for each of the identified pairings, first correlation information correlating the variable of the pairing with another variable appearing in at least one of the constraint conditions of the pairing; registering, in the storage unit, second correlation information correlating, based on a degree of relationship between the variables, at least one of the variables and another variable having at least a predetermined degree of relationship with the at least one variable; and searching for a solution to the 0-1 integer programming problem by determining, based on the first and second correlation information, a group of any two or more correlated variables, for value inversion.

IPC Classes  ?

• G06N 5/01 - Dynamic search techniquesHeuristicsDynamic treesBranch-and-bound

Abstract

This electron beam irradiation device includes: a disposition part for disposing an irradiation target including a photosensitive substance on the inside; and an irradiation unit for emitting an electron beam with energy higher than 1 MeV towards the photosensitive substance inside the irradiation target disposed on the disposition part. The irradiation unit causes the photosensitive substance to react by irradiating the photosensitive substance with the electron beam, and also causes Cherenkov light to be radiated due to propagation of the electron beam in the irradiation target and causes the photosensitive substance to react due to the Cherenkov light.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• A61N 5/06 - Radiation therapy using light

Abstract

Porous particles according to the present invention contain a starch that is modified with an organic acid. The organic acid is a polyvalent carboxylic acid having at least three carboxylate groups per molecule, or a salt thereof. The porous particles according to the present invention are entirely composed of a biodegradable material, and can, when being discarded, reduce the influence on the environmental load. The porous particles of the present invention are useful as a material for sanitary products and agricultural materials, for example.

IPC Classes  ?

• B01J 20/26 - Synthetic macromolecular compounds
• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• B01J 20/30 - Processes for preparing, regenerating or reactivating

Abstract

The present disclosure provides: a method for producing regulatory T (Treg) cells, the method including a step for suppressing the activity of RBPJ in conventional T (Tconv) cells; and Treg cells produced by the method. The present disclosure also provides a drug for inducing Treg cells that can be used in the method of the present disclosure. The present disclosure further provides a drug for immunosuppression, comprising Treg cells produced by the method of the present disclosure or a drug for inducing Treg cells. Drugs for immunosuppression of the present disclosure are useful in the treatment of autoimmune diseases and tissue transplant patients.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 5/14 - Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
• A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents
• A61P 7/06 - Antianaemics
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/06 - Antipsoriatics
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/12 - Genes encoding animal proteins
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms

Abstract

A sterilization device (1) includes a peroxynitric acid gas generation section (10) and a sterilization treatment section (20). The peroxynitric acid gas generation section (10) generates peroxynitric acid gas obtained by gasifying a peroxynitric acid-containing liquid. In so doing, for example, the peroxynitric acid gas generation section (10) generates a peroxynitric acid mist by ultrasonically atomizing the peroxynitric acid-containing and causes the liquid, peroxynitric acid gas to be generated from the peroxynitric acid mist. The sterilization treatment section (20) applies the peroxynitric acid gas to a sterilization target (22) to sterilize the sterilization target (22).

IPC Classes  ?

• A61L 2/22 - Phase substances, e.g. smokes, aerosols
• A01N 25/18 - Vapour or smoke emitting compositions with delayed or sustained release
• A01N 59/00 - Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A61L 2/20 - Gaseous substances, e.g. vapours
• A61L 2/26 - Accessories
• A61L 101/20 - Acids

Abstract

Method for evaluating cardiomyocytes using Raman scattering: a Raman spectrum of cardiomyocytes artificially induced to differentiate from pluripotent stem cells is acquired, an intensity of Raman-scattered light for a protein containing at least one of heme b and heme c as a prosthetic group is acquired from the Raman spectrum, and a state of progress of maturation of the cardiomyocytes is evaluated on the basis of the intensity of the Raman-scattered light. Method for evaluating differentiation into cardiomyocytes using Raman scattering: cells which are pluripotent stem cells are artificially induced to differentiate into cardiomyocytes, a Raman spectrum of the cells induced to differentiate is acquired, an intensity of Raman-scattered light for at least one of heme b and heme c is acquired from the Raman spectrum, and a state of progress of differentiation of the cells into cardiomyocytes is evaluated on the basis of the intensity of the Raman-scattered light.

IPC Classes  ?

• G01N 33/483 - Physical analysis of biological material
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• G01N 21/65 - Raman scattering

Abstract

Provided is an atom concentration device that comprises a molecular beam radiation unit that radiates a molecular beam that includes specific atoms, a laser light source unit that radiates a laser that has a wavelength that excites the specific atoms, and a reflection unit that includes a plurality of mirrors that reflect the laser. The laser light source unit radiates the laser to satisfy a condition under which the specific atoms undergo Rabi oscillation at the reflection unit.

IPC Classes  ?

• B01D 59/34 - Separation by photochemical methods

Abstract

Provided is a biomarker useful for diagnosis of platinum preparation resistance. Also provided is an examination method for determining platinum preparation resistance using the biomarker.　Attention is paid to an EV released from an excised tissue of a cancer site as an EV derived from only a lesion site reflecting the in vivo environment, and it was found that the EV released from the ovarian cancer tissue has a characteristic RNA modification different from that of the EV released from the normal ovarian tissue.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention addresses the problem of providing a technique for improving the antibody-inducing ability of a nasal vaccine, and a composition for nasal administration having improved antibody-inducing ability. The problem is solved by a composition for nasal administration containing: at least one substance selected from the group consisting of antigen polypeptides and polynucleotides including a coding sequence of an antigen polypeptide; and a sugar component that is a sugar and/or a sugar alcohol, wherein the content of the sugar component is more than 4.5% by mass/volume.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 9/10 - DispersionsEmulsions
• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 35/761 - Adenovirus
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 31/04 - Antibacterial agents
• A61P 31/10 - Antimycotics
• A61P 31/12 - Antivirals
• A61P 33/00 - Antiparasitic agents
• A61P 37/04 - Immunostimulants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

A pretreatment method for the analysis of a metabolite includes: a step for supplying an analysis target sample to a porous carrier to support a metabolite contained in the analysis target sample on the porous carrier; and a step for supplying a vaporized derivatization reagent to the porous carrier to which the metabolite has been supported, thereby derivatizing the metabolite.

IPC Classes  ?

• G01N 30/06 - Preparation
• G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
• G01N 30/08 - Preparation using an enricher
• G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups

Abstract

The present invention addresses the problem of providing a device for simultaneously measuring an electric signal and a contractile force by using a highly mature myocardial tissue having a 3D/oriented structure close to myocardial structure in a living body. As a solution, provided is a device for measuring the contractile force of a myocardial tissue, the device comprising a contractile unit which includes a rod-like artificial myocardial tissue having a three-dimensional structure and in which cardiomyocytes are oriented in the longitudinal direction, wherein the device is used for measuring the contractile force of the contractile unit.

IPC Classes  ?

• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• G01N 27/00 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers
• G01N 33/483 - Physical analysis of biological material

Abstract

The present invention addresses the problem of providing a compound that can act as a tracer to detect lymphocyte infiltration into myocardial tissue using positron emission tomography (PET) or the like. The problem is solved by a radioactive positron-emitting nuclide carbon-11 labeled compound ([11C] labeled compound) represented by general formula (I), or a pharmaceutically acceptable salt thereof. (In the formula, R1is a chlorine atom. m is an integer of 1-3. At least one of R2, R3, R4, R5, R6, or R7is a linear or branched C1-6 alkyl group, the alkyl group has radioactive positron-emitting nuclide carbon-11 [11C], and the rest are hydrogen atoms. R8 is a hydrogen atom or a linear or branched C1-6 alkyl group.)

IPC Classes  ?

• C07D 239/96 - Two oxygen atoms
• A61K 51/04 - Organic compounds

Abstract

This formed body includes a binder and a conductive coil, and the average ratio of the longest side to the shortest side in a minimum cuboid surrounding the conductive coil is 1 to 2, inclusive.

IPC Classes  ?

• H05K 9/00 - Screening of apparatus or components against electric or magnetic fields
• C08K 3/08 - Metals
• C08L 101/00 - Compositions of unspecified macromolecular compounds

Abstract

This composite flake contains a binder A and a plurality of conductive materials, and has a surface area in the planar direction of 1 mm2 or less.

IPC Classes  ?

• C08J 3/12 - Powdering or granulating
• C01B 32/158 - Carbon nanotubes
• C08K 3/04 - Carbon
• C08L 1/00 - Compositions of cellulose, modified cellulose, or cellulose derivatives
• C08L 101/00 - Compositions of unspecified macromolecular compounds
• H01B 1/24 - Conductive material dispersed in non-conductive organic material the conductive material comprising carbon-silicon compounds, carbon, or silicon
• H01B 5/00 - Non-insulated conductors or conductive bodies characterised by their form
• H01B 13/00 - Apparatus or processes specially adapted for manufacturing conductors or cables
• H05K 9/00 - Screening of apparatus or components against electric or magnetic fields

Abstract

The present invention addresses the problem of providing a peptide or a composition which can promote the healing of a wound at a dentin-pulp complex. The present invention addresses the problem of providing a peptide or a composition which can promote the healing of a wound at a dentin-pulp complex. The problem can be solved by a peptide that comprises an amino acid sequence comprising Lys-Leu-Leu-Glu-Thr-Glu-Cys-Pro-Gln (SEQ ID NO: 28), an amino acid sequence comprising Asn-Thr-Asp-Gly-Ala-Val-Asn-Phe-Gln (SEQ ID NO: 32), an amino acid sequence comprising Glu-Leu-Val-Arg-Lys-Asp-Leu-Gln-Asn (SEQ ID NO: 47), an amino acid sequence comprising Asn-Ala-Asp-Lys-Gln-Leu-Ser-Phe-Glu (SEQ ID NO: 51), an amino acid sequence having such a structure that 1 to 3 amino acid residues in the amino acid sequence represented by SEQ ID NO: 28, SEQ ID NO: 32, SEQ ID NO: 47 or SEQ ID NO: 51 are substituted or deleted, or an amino acid sequence having such a structure that 1 to 3 amino acid residues are inserted into the amino acid sequence represented by SEQ ID NO: 28, SEQ ID NO: 32, SEQ ID NO: 47 or SEQ ID NO: 51, the peptide having a length of 9 to 15 amino acid residues.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 6/69 - Medicaments
• A61K 6/80 - Preparations for artificial teeth, for filling teeth or for capping teeth
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids

Abstract

A sheet-shaped cell culture comprising skeletal myoblasts for treating liver dysfunction or improving liver function. A method for producing the sheet-shaped cell culture, including a step of seeding a cell population comprising skeletal myoblasts on a culture substrate, a step of forming a sheet of the cell population into a sheet to form a sheet-shaped cell culture, and a step of detaching the formed sheet-shaped cell culture from the culture substrate. A method for treating liver dysfunction, including a step of applying the sheet-shaped cell culture to a site exhibiting the liver dysfunction.

IPC Classes  ?

• A61K 35/34 - MusclesSmooth muscle cellsHeartCardiac stem cellsMyoblastsMyocytesCardiomyocytes
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells

Abstract

The purpose of the present invention is to provide a method that, in a formose reaction which uses formaldehyde as a main raw material, can improve the efficiency of synthesis of sugar by increasing the rate of reaction.　Provided is a method for producing sugar, said method comprising a step in which formaldehyde is used as a substrate, sugar is used as an initiator, and an oxide containing aluminum as cations is caused to act as a catalyst in a buffer solution that has an effective buffer region at a pH of 6-9.

IPC Classes  ?

• C07H 3/02 - Monosaccharides
• C07B 61/00 - Other general methods

Abstract

735273522 nanoparticles, and the average particle diameter of the iron carbide nanoparticles is 30 nm to 800 nm inclusive.

IPC Classes  ?

• B01J 27/22 - Carbides
• B01J 35/45 - Nanoparticles
• B01J 37/08 - Heat treatment
• B01J 37/16 - Reducing
• C01B 32/914 - Carbides of single elements
• C07B 61/00 - Other general methods
• C07C 29/141 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen-containing functional group of C=O containing groups, e.g. —COOH of a —CHO group with hydrogen or hydrogen-containing gases
• C07C 33/20 - Monohydroxylic alcohols containing only six-membered aromatic rings as cyclic part monocyclic

Abstract

Provided is an alloy powder-containing composition that complies with environmental regulations, that operates at high temperatures, and that exhibits superior implementability and bonding reliability. An alloy powder-containing composition according to the present disclosure is characterized by including an alloy powder having an AgSi eutectic structure, silver (Ag) powder, and organic matter. In addition, the content of silver (Ag) relative to the total amount of the alloy powder is preferably 15-97.6 mass%, the content of the silver (Ag) powder is preferably 5-2000 parts by mass with respect to 100 parts by mass of the alloy powder, and the content of silver with respect to the total amount of the alloy powder and the silver (Ag) powder is preferably 20-99.9 mass%.

IPC Classes  ?

• B22F 1/00 - Metallic powderTreatment of metallic powder, e.g. to facilitate working or to improve properties
• B22F 1/14 - Treatment of metallic powder
• B22F 1/052 - Metallic powder characterised by the size or surface area of the particles characterised by a mixture of particles of different sizes or by the particle size distribution
• B22F 7/08 - Manufacture of composite layers, workpieces, or articles, comprising metallic powder, by sintering the powder, with or without compacting of composite workpieces or articles from parts, e.g. to form tipped tools with one or more parts not made from powder
• B22F 9/00 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor
• C22C 5/06 - Alloys based on silver
• H01L 21/52 - Mounting semiconductor bodies in containers

Abstract

The present invention provides an alloy that makes it possible to easily form a sintered body which has excellent joining reliability. An alloy according to the present disclosure is characterized by comprising a phase in which a metal element Y is in solid solution in a metal element X, wherein the metal element X is deposited on a surface via heat treatment in a gas, liquid, or solid atmosphere in which a compound is formed with the metal element Y. The metal element X is preferably deposited on the surface via a heat treatment in an oxygen atmosphere. The metal element X is preferably Ag and/or Cu. It is preferable that the metal element X contains Ag and that the metal element Y contains Si and/or Ge.

IPC Classes  ?

• C22C 5/06 - Alloys based on silver
• B22F 1/00 - Metallic powderTreatment of metallic powder, e.g. to facilitate working or to improve properties
• B22F 1/05 - Metallic powder characterised by the size or surface area of the particles
• B22F 1/10 - Metallic powder containing lubricating or binding agentsMetallic powder containing organic material
• C22C 9/00 - Alloys based on copper
• C22C 27/04 - Alloys based on tungsten or molybdenum
• C22C 27/06 - Alloys based on chromium
• C22C 28/00 - Alloys based on a metal not provided for in groups
• H01B 1/00 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors
• H01B 1/02 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of metals or alloys
• H01B 1/22 - Conductive material dispersed in non-conductive organic material the conductive material comprising metals or alloys
• H05K 1/03 - Use of materials for the substrate
• H05K 3/12 - Apparatus or processes for manufacturing printed circuits in which conductive material is applied to the insulating support in such a manner as to form the desired conductive pattern using printing techniques to apply the conductive material

Abstract

233 as the main component of a matrix component (4), has a thickness of 220 µm or less, and has a light absorption rate of 21% or less with respect to incident light having a wavelength of 630 nm. The matrix component (4) is sintered in a manner surrounding the nitride-based fluorescent component (3), and has an internal quantum efficiency of 70% or more when being irradiated with excitation light having a wavelength of 450 nm.

IPC Classes  ?

• C04B 35/117 - Composites
• C09K 11/08 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials
• C09K 11/64 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing aluminium
• C09K 11/79 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing rare earth metals containing silicon
• C09K 11/80 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing rare earth metals containing aluminium or gallium
• F21V 9/30 - Elements containing photoluminescent material distinct from or spaced from the light source
• F21Y 115/30 - Semiconductor lasers

Abstract

The carbon dioxide recovery system (1) comprises an electrolytic reduction device (2) that generates a producer gas by reducing carbon dioxide, and a carbon dioxide separation device (3) that separates the carbon dioxide from the processed gas. The carbon dioxide separation device is provided with a first gas diffusion electrode (51), a second gas diffusion electrode (52), a liquid chamber (53) formed between the first gas diffusion electrode and the second gas diffusion electrode (52), and is configured to be supplied with an electrolytic liquid containing a compound that adsorbs and desorbs protons in an oxidation-reduction reaction, a first chamber (54) separated from the liquid chamber by the first gas diffusion electrode and configured to be supplied with the producer gas, and a second chamber (55) separated from the liquid chamber by the second gas diffusion electrode and through which the carbon dioxide separated from the producer gas flow. The electrolytic reduction device uses the carbon dioxide separated from the processed gas in the carbon dioxide separation device as a part of an input material thereof.

IPC Classes  ?

• C25B 3/26 - Reduction of carbon dioxide
• B01D 53/26 - Drying gases or vapours
• B01D 53/32 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by electrical effects other than those provided for in group
• B01D 53/62 - Carbon oxides
• C25B 1/23 - Carbon monoxide or syngas
• C25B 3/03 - Acyclic or carbocyclic hydrocarbons
• C25B 9/19 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms
• C25B 11/032 - Gas diffusion electrodes
• C25B 13/02 - DiaphragmsSpacing elements characterised by shape or form
• C25B 15/023 - Measuring, analysing or testing during electrolytic production
• C25B 15/08 - Supplying or removing reactants or electrolytesRegeneration of electrolytes

Abstract

The present invention relates to a compound having light emission characteristics. The compound also has a function as a cell membrane permeation promoter for permeating a cell membrane. The compound is characterized by being represented by general formula (1). (In the formula, R1are the same or different C1-20 straight-chain aliphatic alkyl groups. R2are the same or different C1-17 straight-chain aliphatic alkyl groups or -NR322. R3 are the same or different C1-4 straight-chain aliphatic alkyl groups.)

IPC Classes  ?

• C07C 217/58 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• C07B 61/00 - Other general methods
• C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation

Abstract

22s222s32s2ttO-, s represents a number of 1-8, and t represents a number of 2-10.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided is an alloy powder that is compatible with environmental regulations, and is capable of forming a bonding layer that works at high temperatures and exhibits superior bonding reliability. An alloy powder according to the present disclosure has an AgSi eutectic structure and is characterized in that: one particle is selected from an image obtained by photographing a particle cross section by SEM at a magnification rate of 2,000-50,000 times, the total outer peripheral length of the particle and the length of an outer peripheral part in which the eutectic structure is present, excluding a region where there is no eutectic structure at all in a region 0.2 μm from the outer periphery in the center direction of the particle, are measured; and a method for calculating the ratio with respect to the total outer peripheral length as the ratio of the AgSi structure on the particle surface is performed on any 10 adjacent particles, and the ratio of the AgSi eutectic structure is 10% or more in at least eight of the particles.

IPC Classes  ?

• B22F 1/00 - Metallic powderTreatment of metallic powder, e.g. to facilitate working or to improve properties
• B22F 1/052 - Metallic powder characterised by the size or surface area of the particles characterised by a mixture of particles of different sizes or by the particle size distribution
• B22F 7/08 - Manufacture of composite layers, workpieces, or articles, comprising metallic powder, by sintering the powder, with or without compacting of composite workpieces or articles from parts, e.g. to form tipped tools with one or more parts not made from powder
• B22F 9/00 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor
• C22C 5/06 - Alloys based on silver
• H01L 21/52 - Mounting semiconductor bodies in containers

Abstract

233 as a main component of a matrix component (4), the composite ceramic (1) having a thickness of 220 μm or less and light absorptance of 21% or less with respect to incident light having a wavelength of 630 nm, wherein the matrix component (4) surrounding the nitride-based phosphor component (3) is sintered.

IPC Classes  ?

• C04B 35/117 - Composites
• C09K 11/08 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials
• C09K 11/79 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing rare earth metals containing silicon
• C09K 11/80 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing rare earth metals containing aluminium or gallium
• F21V 9/30 - Elements containing photoluminescent material distinct from or spaced from the light source
• F21Y 115/30 - Semiconductor lasers

Abstract

The present invention aims to provide a method for testing the function of antibodies that uses safe antigens and gives results more quickly. The present invention relates to a method for determining antibody-dependent enhancement ability of antibodies, including contacting, in the presence of a test antibody, Fcγ receptor-expressing cell with single round infectious virus particles containing a gene with a region encoding a labeled protein and a region encoding non-structural (NS) proteins 1 to 5 of the yellow fever virus genome, a capsid protein of a virus, and an outer shell protein (Envelope) of a virus, wherein when the measured label is greater than that of a negative control cell, the test antibody is determined to have an antibody-dependent enhancement ability, and the like.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

Provided are a new pharmaceutical composition and a method for treating and/or preventing autism spectrum disorder, fragile X syndrome, and/or an autism spectrum disorder-like symptom. A pharmaceutical composition for the treatment and/or prevention of autism spectrum disorder, fragile X syndrome, and/or an autism spectrum disorder-like symptom, comprising buprenorphine or a pharmaceutically acceptable salt thereof and/or morphine or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

An ophthalmic examination apparatus includes a visual target projection system that includes a visual target presentation portion that presents a fixed visual target to left and right subject eyes, an objective measurement optical system that objectively measures eye characteristics of the left and right subject eyes, and a controller that controls each portion of the apparatus, wherein the controller measures the eye characteristics of the left and right subject eyes with the objective measurement optical system and acquires an objective refraction value as objective measurement information when fusion is attempted with left and right subject eyes with respect to a change in the convergence distance.

IPC Classes  ?

• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• A61B 3/06 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing light sensitivity, e.g. adaptationSubjective types, i.e. testing apparatus requiring the active assistance of the patient for testing colour vision
• A61B 3/08 - Subjective types, i.e. testing apparatus requiring the active assistance of the patient for testing binocular or stereoscopic vision, e.g. strabismus
• A61B 3/14 - Arrangements specially adapted for eye photography

Abstract

An ophthalmic examination apparatus includes a visual target projection system including a visual target presentation portion that presents a fixed visual target to left and right subject eyes, an objective measurement optical system that objectively measures eye characteristics of the left and right subject eyes, and a controller that controls each portion of the apparatus, wherein the fixed visual target is a visual target for the left eye and a visual target for the right eye that are to be respectively projected to the left and right subject eyes and have a same drawing pattern in positions where up and down direction positions to visual target flames are the same.

IPC Classes  ?

• A61B 3/032 - Devices for presenting test symbols or characters, e.g. test chart projectors
• A61B 3/18 - Arrangement of plural eye-testing or -examining apparatus

Abstract

Provided is an oncolytic adenovirus (Ad) of which the basic skeleton is an Ad having a different serotype from that of an adenovirus type-5 (Ad type-5), and which has high virus yield and can exhibit a satisfactory anti-tumor effect. Also provided is a pharmaceutical composition containing the oncolytic Ad as an active ingredient. The oncolytic Ad is a recombinant oncolytic Ad characterized in that a part or the whole of E1 gene of an Ad type-5 is incorporated into an E1 region in the genome of an Ad having a different serotype from that of the Ad type-5 and a part or the whole of E4 gene of the Ad type-5 is incorporated into an E4 region in the genome of the Ad having a different serotype from that of the Ad type-5.

IPC Classes  ?

• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• A61K 35/761 - Adenovirus
• A61P 35/00 - Antineoplastic agents
• C12N 15/35 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus

Abstract

An object of the present invention is to provide a pharmaceutical composition for preventing and/or treating heart failure. The invention relates to a pharmaceutical composition for preventing and/or treating heart failure, comprising a compound represented by formula (1), a salt thereof, or a prodrug thereof: An object of the present invention is to provide a pharmaceutical composition for preventing and/or treating heart failure. The invention relates to a pharmaceutical composition for preventing and/or treating heart failure, comprising a compound represented by formula (1), a salt thereof, or a prodrug thereof: wherein A is an optionally substituted benzene ring; B is an optionally substituted aryl or an optionally substituted heteroaryl; X is an oxygen atom or a sulfur atom; Y is a nitrogen atom or a carbon atom; of Y is a single or double bond when Y is a carbon atom, or of Y is a single bond when Y is a nitrogen atom; each R1 independently represents lower alkyl, or two R1s may be bound to each other to form a spiro ring or a crosslinked structure, or two R1s may be bound to each other to form a saturated fused heterocycle together with nitrogen and carbon atoms constituting a ring containing Y; p is 0, 1, or 2; or (R1)p is oxo.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4995 - Pyrazines or piperazines forming part of bridged ring systems
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure

Abstract

The present invention provides a sensor system capable of efficiently extracting a feature amount from a sensor detection value. An analysis unit (48) of a sensor system (1) performs at least one of using at least one value among sensor detection values as a reference value to generate an analysis value on the basis of the reference value, generating the analysis value by statistically analyzing the same type or a plurality of types of feature amounts of the sensor detection values, and generating the analysis value by referring to data indicating a relationship between the sensor detection value and a state of a structure. Disturbance influence included in the analysis value is less than disturbance influence included in the sensor detection value.

IPC Classes  ?

• G01N 27/02 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
• G01M 99/00 - Subject matter not provided for in other groups of this subclass
• G01N 27/20 - Investigating the presence of flaws

Abstract

The present invention provides a composition for molding a conductive article having high conductivity. Provided is a composition for molding a conductive article, the composition containing a polythiophene compound represented by general formula (A), ammonia, and an amine compound. Also provided is a method for molding a conductive article using said composition. In general formula (A), L is an alkylene or the like. Each of M1and M2independently represents an alkyl group or a hydrogen atom. R1Ais a hydrogen atom, an alkyl group, an alkoxy group, an acyl group, or a group represented by formula (15). L1, M1cand M2care the same as L, M1and M2, respectively.

IPC Classes  ?

• C08L 65/00 - Compositions of macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chainCompositions of derivatives of such polymers
• C08K 3/28 - Nitrogen-containing compounds
• C08K 5/17 - AminesQuaternary ammonium compounds
• H01B 1/12 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances organic substances

Abstract

The present invention provides a vaccine composition containing a complex of a T cell receptor antigen peptide and a B cell receptor antigen peptide and capable of inducing the production of an antibody against IL-23, wherein the B cell receptor antigen peptide is represented by the following formula (I): The present invention provides a vaccine composition containing a complex of a T cell receptor antigen peptide and a B cell receptor antigen peptide and capable of inducing the production of an antibody against IL-23, wherein the B cell receptor antigen peptide is represented by the following formula (I): X1-X2-X3-X4-X5-X6-X7-X8   (I) The present invention provides a vaccine composition containing a complex of a T cell receptor antigen peptide and a B cell receptor antigen peptide and capable of inducing the production of an antibody against IL-23, wherein the B cell receptor antigen peptide is represented by the following formula (I): X1-X2-X3-X4-X5-X6-X7-X8   (I) wherein X1 is S, A, G, T, K, or R, X2 is P, A, G, S, T, K, or R, X3 is S, A, G, T, K, or R, X4 is Q, A, G, T, or N, X5 is P, A, G, S, T, Q, or N, X6 is W, A, Y, or E, X7 is Q, A, G, T, or N, and X8 is R, A, G, or K.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Abstract

A genome editing method utilizing recombination between homologous chromosomes having different bases at the target site is disclosed. Specifically, (1) a method of using cells in which the function of a gene selected from the group of Lig4 gene, PARP1 gene, XRCC1 gene, MSH2 gene, and SMARCAL1 gene is suppressed, or (2) a method of causing a single-strand break at one site in the neighboring DNA region of the target site on the chromosome of the recipient, and causing a single-strand break at one site different from the site corresponding to the site where the single-strand break is caused on the chromosome of the recipient, on the chromosome of the donor.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The present invention relates to a method for changing a hydrogel volume, the method including a step A of bringing an ionic polymer into contact with a hydrogel, which has a site having decomposition activity for the ionic polymer and a cross-linkable functional group that is capable of cross-linking with the ionic polymer through electrostatic interaction, to allow the cross-linkable functional group to cross-link with the ionic polymer, and reducing a volume of the hydrogel; and a step B of decomposing the ionic polymer cross-linking with the hydrogel by using the site having decomposition activity and discharging at least part of a decomposition product of the ionic polymer from the hydrogel to increase the hydrogel volume.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 9/06 - OintmentsBases therefor
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
• C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
• C08L 89/00 - Compositions of proteinsCompositions of derivatives thereof

Abstract

An ophthalmologic apparatus includes a visual target presenting portion that presents fixation targets to subject eyes; an objective measurement optical system that objectively measures eye characteristics of the subject eyes; and a controller. Each of the fixation targets includes fusion targets depicted in a manner that allows binocular fusion while the subject eyes respectively view the fixation targets. The visual target presenting portion presents the fixation targets while changing an examination distance from the subject eyes to the fixation target when an anisometropia is induced. In the anisometropia, one subject eye is in a fully corrected condition and the other subject eye is corrected by a predetermined degree from the fully corrected condition. The controller controls the objective measurement optical system to measure the eye characteristics while the subject eyes binocularly view the fixation targets and acquire refractive values of the subject eyes as objective measurement information.

IPC Classes  ?

• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• A61B 3/103 - Objective types, i.e. instruments for examining the eyes independent of the patients perceptions or reactions for determining refraction, e.g. refractometers, skiascopes

Abstract

According to one embodiment, a liquid crystal optical element includes a transparent substrate, and a liquid crystal layer which faces the transparent substrate and has a cholesteric liquid crystal and an additive exhibiting liquid crystallinity. Refractive anisotropy of the additive is less than refractive anisotropy of the liquid crystal layer.

IPC Classes  ?

• G02B 5/30 - Polarising elements
• C09K 19/30 - Non-steroidal liquid crystal compounds containing at least two non-condensed rings containing saturated or unsaturated non-aromatic rings, e.g. cyclohexane rings
• C09K 19/36 - Steroidal liquid crystal compounds
• C09K 19/50 - Mixtures of liquid crystal compounds covered by two or more of the preceding groups containing steroidal liquid crystal compounds

Abstract

Cognitive function evaluation system (100) includes motion detector (20), answer detector (30), and evaluator (40). Motion detector (20) generates frames representing three-dimensional coordinates of joints of subject (SJ) who is performing a predetermined task. The predetermined task includes a physical task and a cognitive task that requires subject (SJ) to answer questions on a cognitive examination. Motion detector (20) capture images of subject (SJ) to generate the frames. The frames are a series of frames generated in time order. Answer detector (30) detects answers to questions on the cognitive examination by subject (SJ). Evaluator (40) outputs motion features based on the frames and evaluates a cognitive function of subject (SJ) based on the motion features and the answers by subject (SJ). The motion features represent a feature of a spatial positional relationship and a feature of temporal variations, of the joints of subject (SJ) in the captured images.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• G06T 7/246 - Analysis of motion using feature-based methods, e.g. the tracking of corners or segments
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

An organ model for a medical device, which is held in a container in a state of being filled with a liquid and into which a catheter can be inserted through insertion parts provided on the container, comprise a soft member including a holding part that is held in the container, and a hard member including a plate-shaped part installed on the inner surface of the container and being integrated with the soft member, wherein the hard member is not fixed to the container, is attachable to or detachable from the soft member, and is positioned by being connected to the soft member.

IPC Classes  ?

• G09B 23/28 - Models for scientific, medical, or mathematical purposes, e.g. full-sized device for demonstration purposes for medicine

Abstract

An information transmission device (2) comprises: a transmission voice generation unit (12) that generates a transmission voice indicating a transmission content; an additional voice generation unit (14) that generates an additional voice; and a voice output unit (10) that simultaneously outputs the generated transmission voice and additional voice to a subject. The additional voice is a voice for improving the listening comprehension of the transmission sound by the subject as compared with a case where only the transmission sound out of the transmission sound and the additional sound is outputted to the subject.

IPC Classes  ?

• G10L 21/0364 - Speech enhancement, e.g. noise reduction or echo cancellation by changing the amplitude for improving intelligibility
• G10L 21/057 - Time compression or expansion for improving intelligibility

Abstract

To provide a group III nitride seed crystal substrate for use in a method for producing a group III nitride crystal having a large size and few defects. The group III nitride seed crystal substrate is used in a method for producing a group III nitride crystal, and comprises a substrate and a plurality of group III nitride seed crystals disposed over the entire flat surface of the main surface of the substrate.

IPC Classes  ?

• C30B 29/38 - Nitrides
• C30B 19/02 - Liquid-phase epitaxial-layer growth using molten solvents, e.g. flux
• C30B 25/00 - Single-crystal growth by chemical reaction of reactive gases, e.g. chemical vapour deposition growth

Abstract

A molded rigid polymer article production method includes forming a molded rigid polymer article from a rigid-polymer-dispersed liquid and drying the molded rigid polymer article. The rigid-polymer-dispersed liquid contains a polar medium and rigid polymers dispersed in the polar medium. The molded rigid polymer article is derived from the rigid polymers deposited on at least one of first and second electrodes. In the forming, the at least one includes a surface on which the rigid polymers are deposited, and convex or concave portions at the surface. The convex or concave portions are larger than a thickness of the molded rigid polymer article.

IPC Classes  ?

• B29C 41/02 - Shaping by coating a mould, core or other substrate, i.e. by depositing material and stripping-off the shaped articleApparatus therefor for making articles of definite length, i.e. discrete articles
• B29C 41/42 - Removing articles from moulds, cores or other substrates
• B29L 31/00 - Other particular articles

Abstract

Provided are a compound library generation method and the like that make it possible to construct a compound library that increases the proportion of compounds that have ability to bind to a target.　A compound library generation method according to the present invention involves a computer executing processing that acquires information about a plurality of compounds stored at a first compound library, uses a learning model that has been trained to output information that indicates ability to bind to a target substance when compound information about a compound has been inputted to sort the plurality of compounds stored at the first compound library into a group of compounds that have ability to bind to a target substance and a group of compounds that do not have ability to bind to the target substance, and generates a second compound library that includes the compounds sorted into the group of compounds that have ability to bind to the target substance.

IPC Classes  ?

• G16C 20/62 - Design of libraries
• G16C 20/70 - Machine learning, data mining or chemometrics

Abstract

The present invention addresses the problem of providing a lung cancer biomarker and a method for using the same. The aforementioned problem is solved by a method for testing for lung cancer, the test method including (1) a step for detecting at least one protein selected from the group consisting of a protein group (A), a protein group (B), a protein group (C), a protein group (D), and a protein group (E) in a bodily fluid or extracellular vesicles of a bodily fluid collected from a subject.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

An object is to provide a novel antibody or antigen-binding fragment thereof against exon 21 of human periostin. The object is achieved by an antibody or antigen-binding fragment thereof bindable to a conformational epitope on human periostin, wherein the epitope contains the amino acid sequence A represented by SEQ ID NO: 61 and the amino acid sequence B represented by any one of SEQ ID NOs: 62 to 64.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

A nucleic acid encoding a miniatureized hemagglutinin complex protein, wherein the miniaturized hemagglutinin complex protein has function inhibitory activity against E-cadherin, and wherein the miniaturized hemagglutinin complex protein is selected from the group consisting of: (1) mini-HA consisting of HA1 subcomponent of SEQ ID NO: 10, HA2 subcomponent of SEQ ID NO: 4, and HA3 subcomponent fragment of SEQ ID NO: 2, (2) FL(2+3)-C consisting of HA2 subcomponent of SEQ ID NO: 4 and HA3 component with Strep-Tag (C-terminus) of SEQ ID NO: 44, (3) linked-mini (2+3)/BB of SEQ ID NO: 47, (4) linked-mini (2+3)/CB of SEQ ID NO: 48, (5) linked-mini (2+3)/CB-YFDY of SEQ ID NO: 49, and (6) linked-mini (2+3)/CB-LD/YFDY of SEQ ID NO: 50.

IPC Classes  ?

• C07K 14/33 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Clostridium (G)
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

One drug (preparation) of the present invention is a drug for a reproductive disorder containing a silicon fine particle, an aggregate of silicon fine particles or a crystal grain of silicon having a hydrogen-generating ability. Hydrogen generated from the silicon fine particle in the drug can contribute to the prevention and/or treatment of reproductive disorder.

IPC Classes  ?

• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61K 9/14 - Particulate form, e.g. powders

Abstract

A neurofeedback system (100) for achieving an effective NF system using SWRs comprises: a brain wave signal acquisition unit (11) that acquires a brain wave signal measured in a patient; and a feedback unit (an index calculation unit 12, an output control unit 14) that calculates an index related to a sharp wave ripple included in the acquired brain wave signal in real time and allows the patient to recognize the calculated index in real time.

IPC Classes  ?

• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
• A61B 5/375 - Electroencephalography [EEG] using biofeedback

Abstract

Provided are a polarizing agent that can selectively enhance NMR signals by the DNP-NMR method even in a reducing environment, and a method for selectively enhancing NMR signals. The present invention is a polarizing agent for use in the DNP-NMR method, the polarizing agent comprising nanodiamond particles, and the nanodiamond particles having a surface modified with a functional group capable of covalently binding to or interacting with proteins. The polarizing agent of the present invention can selectively enhance NMR signals by the DNP-NMR method even in a reducing environment.

IPC Classes  ?

• G01R 33/28 - Details of apparatus provided for in groups
• A61K 49/10 - Organic compounds
• G01N 24/08 - Investigating or analysing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Provided is a high-function organoid composition. Also provided is a method of producing the organoid composition. The organoid composition is characterized by including: an organoid including a cell cluster of endodermal cells; and an amphiphilic block polymer having a hydrophilic block chain having a sarcosine unit and a hydrophobic block chain having a lactic acid unit. The organoid composition may be produced by culturing the endodermal cells in a culture system containing the amphiphilic block polymer. The organoid composition thus obtained can evaluate pharmacokinetics and drug toxicity, and is hence suitable for drug screening.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The purpose of the present invention is to provide a treatment for treating and/or preventing inflammatory bowel disease, such as ulcerative colitis or Crohn's disease.　The present invention relates to a pharmaceutical or food composition for treating and/or preventing inflammatory bowel disease, the pharmaceutical or food composition containing a compound represented by formula (I) [in the formula, R1 is hydrogen, a substituted or unsubstituted alkyl, a substituted or unsubstituted alkenyl, a substituted or unsubstituted alkynyl, a substituted or unsubstituted aryl, a substituted or unsubstituted heteroaryl, a substituted or unsubstituted cycloalkyl, or a substituted or unsubstituted cycloalkenyl or a substituted or unsubstituted heterocyclyl] or a pharmacologically acceptable salt thereof.

IPC Classes  ?

• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 31/232 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

The problem addressed by the present invention is to recognize a change of the condition of a subject. An information processing device (1) comprises: a data acquisition unit (21) that acquires medical examination data about the subject; a classification unit (22) that inputs the acquired medical examination data about the subject to a classification model that can classify the subject into any one of a plurality of expression types on the basis of the medical examination data, and classifies the subject into any one of the plurality of expression types; and a subject transition information output unit (23) that outputs subject transition information indicating a transition of the subject from a first classification result to a second classification result.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

This medical instrument processing member (100) capable of improving workability comprises a heating unit (2). The heating unit (2) has a first internal space (2a). The heating unit (2) is a bag-shaped member including a heat-generating element (4). In the heating unit (2), a first opening (2b) continued to the first internal space (2a) of the heating unit (2) is formed. The outer peripheral shape of the heating unit (2) may be cylindrical. The heat-generating element (4) may react with air to generate heat by oxidation. The medical instrument processing member (100) may comprise a wiping unit (1). The wiping unit (1) may be connected to the heating unit (2).

IPC Classes  ?

• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor
• A61B 1/12 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with cooling or rinsing arrangements
• A61M 5/44 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests having means for cooling or heating the devices or media

Abstract

The present invention relates to a composition for use in vaccines, the composition containing a cationic lipid represented by formula (1).

IPC Classes  ?

• A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

In a distributed feedback semiconductor laser element, a multi-layered structure includes a GaN substrate, an n-type semiconductor layer, an active layer, and a p-type semiconductor layer, and a ridge waveguide is formed. A first diffraction grating is formed adjacent to and on both sides of the ridge waveguide. A depth d of a groove of the first diffraction grating is included in the range of 50 nm d≤200 nm, and a duty ratio duty is included in the range of an inequality (1) using constants a, b, c, and n defined for the order of the diffracted light. In a distributed feedback semiconductor laser element, a multi-layered structure includes a GaN substrate, an n-type semiconductor layer, an active layer, and a p-type semiconductor layer, and a ridge waveguide is formed. A first diffraction grating is formed adjacent to and on both sides of the ridge waveguide. A depth d of a groove of the first diffraction grating is included in the range of 50 nm d≤200 nm, and a duty ratio duty is included in the range of an inequality (1) using constants a, b, c, and n defined for the order of the diffracted light. - d - c a n + b ≦ duty ≦ d - c a n + b ( 1 )

IPC Classes  ?

• H01S 5/12 - Construction or shape of the optical resonator the resonator having a periodic structure, e.g. in distributed feedback [DFB] lasers
• H01S 5/22 - Structure or shape of the semiconductor body to guide the optical wave having a ridge or a stripe structure

Abstract

Provided is an isotope enrichment and separation method for concentrating and separating an isotopic element efficiently and at low cost even when the element has no gas compound. According to this isotope enrichment and separation method, with which a target isotope is concentrated and separated from an element in which different isotopes are present: an aqueous solution of an element compound in which different isotopes are present is prepared and then set in a centrifugal separator; a centrifugal force of the centrifugal separator is caused to act on the aqueous solution to cause the isotopes in the aqueous solution to migrate so as to change the concentration distribution of the isotopes in the aqueous solution in a gradual manner; and the aqueous solution located at the position of the desired isotope in the concentration distribution is separated out to perform concentration and separation of the target isotope.

IPC Classes  ?

• B01D 59/20 - Separation by centrifuging

Abstract

This laminate comprises: a piezoelectric layer containing lead; a metal layer laminated on the piezoelectric layer and containing vanadium; and a first ferromagnetic layer laminated on the piezoelectric layer with the metal layer interposed therebetween. As a result of intensive research by the present inventors, it has been found that the induced magnetic anisotropy energy of the first ferromagnetic layer depends on the sample structure of the first ferromagnetic layer and the metal layer containing vanadium. By utilizing this point, a binary property can be controlled by adjusting the sample structure of the first ferromagnetic layer or the metal layer and changing the induced magnetic anisotropy energy. Thus, with the laminate, it is possible to easily control a binary property.

IPC Classes  ?

• H10N 50/10 - Magnetoresistive devices
• H10B 61/00 - Magnetic memory devices, e.g. magnetoresistive RAM [MRAM] devices

Abstract

The present invention found that, for example, inhibiting phosphorylation of a Ser residue in Regnase-1 is effective in treating and/or preventing diseases. The invention also found that, for example, inhibiting the binding of Regnase-1 with at least one factor selected from the group consisting of TBK1, IKKi, Act-1, IKK, and IRAK is effective in treating and/or preventing diseases.

IPC Classes  ?

• A61K 38/45 - Transferases (2)
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 17/06 - Antipsoriatics
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 27/02 - Ophthalmic agents
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 7/64 - Cyclic peptides containing only normal peptide links
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
• G01N 33/573 - ImmunoassayBiospecific binding assayMaterials therefor for enzymes or isoenzymes

Abstract

The present invention provides an Al-ND-based composite material in which nanodiamond (ND) particles are dispersed in an aluminum (Al)-based metal matrix.

IPC Classes  ?

• C22C 26/00 - Alloys containing diamond
• B22F 1/18 - Non-metallic particles coated with metal
• B22F 3/105 - Sintering only by using electric current, laser radiation or plasma
• B22F 3/24 - After-treatment of workpieces or articles
• B22F 9/04 - Making metallic powder or suspensions thereofApparatus or devices specially adapted therefor using physical processes starting from solid material, e.g. by crushing, grinding or milling
• C22C 1/059 - Making alloys comprising less than 5% by weight of dispersed reinforcing phases

Abstract

A graphene grid that can reduce or prevent uneven distribution, uneven orientation, and the like of a structural analysis target substance, and can capture the structural analysis target substance with high efficiency and analyze the structural analysis target substance with high resolution, in structural analysis by cryo-electron microscopy. To achieve the above object, the graphene grid has a graphene surface onto which a functional group containing at least one of a silicon atom or a phosphorus atom is introduced.

IPC Classes  ?

• H01J 37/20 - Means for supporting or positioning the object or the materialMeans for adjusting diaphragms or lenses associated with the support
• C01B 32/194 - After-treatment
• G01N 1/36 - Embedding or analogous mounting of samples

Abstract

Provided is an irradiation device that is capable of effectively suppressing activities of insect pests. An irradiation device (100) includes: a detection section (31) that detects an insect which is an irradiation target; an identification section (32) that identifies position information of the irradiation target; and an irradiation section (1) that, based on the position information, irradiates the irradiation target with shooting laser light (L2) while targeting a specific part of the irradiation target.

IPC Classes  ?

• A01M 1/22 - Stationary means for catching or killing insects by electric means
• G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods

Abstract

A method for generating spectral data according to the present invention involves generating spectral data pertaining to a microparticle sample that includes at least one microparticle, wherein: the method includes a step for acquiring a measurement spectrum from microparticles disposed within a through-hole in a substrate; the through-hole has an inclined structure in which the width continuously decreases from one surface of the substrate toward the other surface thereof; at least part of the inner surface of the through-hole is configured from a metal that exhibits plasmon resonance; and in the step for acquiring the measurement spectrum, the measurement spectrum is acquired while the interior of the through-hole is irradiated with light.

IPC Classes  ?

• G16C 20/20 - Identification of molecular entities, parts thereof or of chemical compositions
• G16C 20/70 - Machine learning, data mining or chemometrics

Abstract

The present invention provides: a prophylactic or ameliorating agent for cachexia, which contains a phospholipid and/or a lysophospholipid as an active ingredient; and a method for screening for a substance capable of ameliorating cachexia. The prophylactic or ameliorating agent for cachexia according to the present invention is effective not only against cancer cachexia but also against cachexia induced by a disease other than cancer, can suppress the decrease in a skeletal muscle mass, can suppress fat atrophy, and can suppress the expression of inflammatory cytokines.

IPC Classes  ?

• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• A61P 31/04 - Antibacterial agents
• A61P 35/00 - Antineoplastic agents
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/06 - Quantitative determination
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

A spectrometry device (1) according to an embodiment of the present invention comprises: a first fiber unit (70) into which irradiation light enters; a portable unit (80) to which the first fiber unit is connected; a spectroscope (50) which diffracts a signal light; a second fiber unit (40) which is connected to the portable unit (80) and in which a plurality of second fibers are arranged adjacent to each other on an incident end surface, and a plurality of fibers are arranged in a multi-line shape so as to be spaced apart on an emission end surface; and a processing unit that generates a spectral image of a sample from a detection result of a two-dimensional array photodetector by referring to the arrangement relationship between the plurality of fibers on the incident end surface and the emission end surface of the second fiber unit (40).

IPC Classes  ?

• G01J 3/02 - SpectrometrySpectrophotometryMonochromatorsMeasuring colours Details
• A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
• G01J 3/36 - Investigating two or more bands of a spectrum by separate detectors
• G01J 3/44 - Raman spectrometryScattering spectrometry
• G01N 21/65 - Raman scattering

Abstract

The present invention addresses the problem of providing: a protein that acts as a scintillator; and a method for designing a protein that acts as a scintillator. According to the present invention, a use of a β-barrel-type fluorescent protein as a scintillator is provided, wherein the β-barrel-type fluorescent protein has a fluorescence peak at 500 nm or less. According to the present invention, a method for designing a protein that acts as a scintillator is also provided, the method comprising (A) a step for identifying a specific amino acid residue in an amino acid sequence for a β-barrel-type fluorescent protein being mutated and (B) a step for constructing, on the basis of the amino acid sequence for the protein being mutated, an amino acid sequence having a structure such that the amino acid residue identified in the step (A) is substituted by another specific amino acid residue.

IPC Classes  ?

• C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12N 1/13 - Unicellular algaeCulture media therefor modified by introduction of foreign genetic material
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/09 - Recombinant DNA-technology
• C12N 15/12 - Genes encoding animal proteins
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

The present disclosure provides an apparatus and a method for manufacturing a composite. In one aspect, the present disclosure provides a method for manufacturing a formulation comprising a first component and a second component. This method includes: a step for preparing a series of flow paths in which a first flow path through which a first fluid flows at a first flow velocity and a second flow path through which a second fluid flows at a second flow velocity are combined at a merging portion to form a third flow path through which a third fluid flows at a third flow velocity; a step in which the first component is injected into the first flow path at a first time; and a step in which the second component is injected into the second flow path at a second time. The first time and the second time are set so that the first component and the second component reach the merging portion at a timing when the components are mixed.

IPC Classes  ?

• B01F 23/45 - Mixing liquids with liquidsEmulsifying using flow mixing
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• B01F 25/43 - Mixing tubes, e.g. wherein the material is moved in a radial or partly reversed direction
• B01F 33/301 - Micromixers using specific means for arranging the streams to be mixed, e.g. channel geometries or dispositions
• B01F 35/22 - Control or regulation
• B01F 35/71 - Feed mechanisms
• B01F 35/75 - Discharge mechanisms
• B01F 35/92 - Heating or cooling systems for heating the outside of the receptacle, e.g. heated jackets or burners
• B01F 35/213 - Measuring of the properties of the mixtures, e.g. temperature, density or colour
• B01F 35/221 - Control or regulation of operational parameters, e.g. level of material in the mixer, temperature or pressure
• B01J 2/10 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
• B01F 101/22 - Mixing of ingredients for pharmaceutical or medical compositions

Abstract

Provided is a biomarker useful for the diagnosis of cancer and the development of new drugs. Further provided are a cancer examination method, a treatment agent, and a reagent for studies of cancer, in each of which the biomarker is used. A useful biomarker is provided by identifying a protein that is expressed on the surface of the membrane of an extracellular vesicle (EV) in a cancer-specific manner. The cancer examination method includes detecting a protein (biomarker) that is expressed, in a cancer-specific manner, on the surface of the membrane of an EV contained in a collected body fluid specimen to detect a cancer-specific EV. An antibody against a protein expressed on the surface of the membrane of an EV in a cancer-specific manner can be used in a cancer examination method, a cancer treatment agent, and a reagent for studies of cancer.

IPC Classes  ?

• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

This sterilization device (1) comprises: a first container (12) that accommodates an object (A01); a first decompression unit (14) that decompresses the first container; and a supply unit (15) that supplies a pernitric acid gas to the object placed under a decompressed condition provided by the first decompression unit. The sterilization device can sterilize deep portions of the object.

IPC Classes  ?

• A61L 2/20 - Gaseous substances, e.g. vapours

Abstract

Provided is a wavelength conversion element in which high-quality crystal part can be utilized by a simple configuration. This wavelength conversion element comprises a substrate having a main surface, and an optical waveguide disposed on the main surface of the substrate, a core of the optical waveguide including a polar member having a second-order nonlinear optical constant and a first non-polar member disposed adjacent to the polar member in a direction parallel to the main surface of the substrate, and one or both side surfaces of the polar member and the first non-polar member being in contact with each other in a cross section orthogonal to the optical axis of the optical waveguide.

IPC Classes  ?

• G02F 1/377 - Non-linear optics for second-harmonic generation in an optical waveguide structure

Abstract

The present disclosure provides an apparatus and a method for taking out a particular fraction from a flow path. More particularly, in one aspect, the present disclosure provides a method for taking out a particular fraction from a flow path. The method includes: a step for flowing a component through the flow path; a step for taking out a fraction from the collection part on the flow path by means of a dispenser provided with a valve; and a step for distributing the fraction to the receiving part. In one embodiment, the collection part is positioned in a middle portion of the flow path (a portion that is neither an inflow port nor an outflow port of the flow path).

IPC Classes  ?

• G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• B01F 23/45 - Mixing liquids with liquidsEmulsifying using flow mixing
• B01F 25/43 - Mixing tubes, e.g. wherein the material is moved in a radial or partly reversed direction
• B01F 33/301 - Micromixers using specific means for arranging the streams to be mixed, e.g. channel geometries or dispositions
• B01F 35/75 - Discharge mechanisms
• B01F 35/213 - Measuring of the properties of the mixtures, e.g. temperature, density or colour
• B01F 35/221 - Control or regulation of operational parameters, e.g. level of material in the mixer, temperature or pressure
• B01J 2/10 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic in stationary drums or troughs, provided with kneading or mixing appliances
• B01J 4/00 - Feed devicesFeed or outlet control devices
• B01J 13/02 - Making microcapsules or microballoons
• B01F 101/04 - Mixing biocidal, pesticidal or herbicidal ingredients used in agriculture or horticulture, e.g. for spraying
• B01F 101/06 - Mixing of food ingredients
• B01F 101/21 - Mixing of ingredients for cosmetic or perfume compositions
• B01F 101/22 - Mixing of ingredients for pharmaceutical or medical compositions

Abstract

Provided is a method for detecting an abnormal cell having a gene mutation, the method comprising: a step for amplifying a region corresponding to a region comprising a nucleotide sequence lying between a nucleotide located at position-1,316 and a nucleotide located at position-1,663 in SEQ ID NO:1 and/or a region corresponding to a region comprising a nucleotide sequence lying between a nucleotide located at position-1,931 and a nucleotide located at position-2,642 in SEQ ID NO: 1 to produce an amplification product, wherein SEQ ID NO:1 is included in genomic DNA derived from a peripheral blood mononuclear cell of the patient; and a step for determining the nucleotide sequence for the amplification product and detecting a nucleotide mutation. In the method, the presence of the lesion is indicated when the nucleotide mutation is detected, and the amplification is performed by a PCR using a primer having no additional sequence.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6869 - Methods for sequencing
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The purpose is to provide a novel luminescence-related gene (nucleic acid, vector for expression) capable of imparting stronger luminescence than by known luminescence-related genes to an organism (in particular, a plant).　Provided is a nucleic acid containing at least one base sequence selected from: a base sequence encoding a protein containing an amino acid sequence represented by SEQ ID NO: 1 or an amino acid sequence having 90% or more sequence identity with a sequence represented by SEQ ID NO: 1; a base sequence encoding a protein containing an amino acid sequence represented by SEQ ID NO: 2 or 3 or an amino acid sequence having 90% or more sequence identity with a sequence represented by SEQ ID NO: 2 or 3; a base sequence encoding a protein containing an amino acid sequence represented by SEQ ID NO: 4 or 5 or an amino acid sequence having 90% or more sequence identity with a sequence represented by SEQ ID NO: 4 or 5; and a base sequence encoding a protein containing an amino acid sequence represented by SEQ ID NO: 6 or an amino acid sequence having 90% or more sequence identity with a sequence represented by SEQ ID NO: 6.

IPC Classes  ?

• C12N 15/53 - Oxidoreductases (1)
• A01H 1/00 - Processes for modifying genotypes
• A01H 5/00 - Angiosperms, i.e. flowering plants, characterised by their plant partsAngiosperms characterised otherwise than by their botanic taxonomy
• A01H 6/82 - Solanaceae, e.g. pepper, tobacco, potato, tomato or eggplant
• C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
• C12N 5/04 - Plant cells or tissues
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/55 - Hydrolases (3)
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

One purpose of the present invention is to provide a resin film and a metal-clad laminate, each of which enables the production of a printed wiring board that has excellent dimensional stability, while being reduced in transmission loss. Another purpose of the present invention is to provide a method for producing a resin film that enables the production of a printed wiring board that has excellent dimensional stability, while being reduced in transmission loss. The present invention relates to a resin film 7 which comprises a polyimide film 70 and a PTFE film 71 that is directly superposed on the polyimide film 70. With respect to the resin film 7, the peeling strength at the time when the PTFE film 71 is peeled is 0.5 N/mm or more.

IPC Classes  ?

• B32B 27/08 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance of synthetic resin of a different kind
• B29C 65/02 - Joining of preformed partsApparatus therefor by heating, with or without pressure
• B32B 15/08 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin
• B32B 27/30 - Layered products essentially comprising synthetic resin comprising vinyl resinLayered products essentially comprising synthetic resin comprising acrylic resin
• B32B 27/34 - Layered products essentially comprising synthetic resin comprising polyamides
• C08J 7/00 - Chemical treatment or coating of shaped articles made of macromolecular substances
• H05K 1/03 - Use of materials for the substrate

Abstract

A permanent magnet-type rotary electric machine comprises: a stator including: a stator core having a plurality of stator teeth formed circumferentially; stator coils arranged in the respective bottoms of a plurality of stator slots formed between the stator teeth and wound on the stator teeth in a concentrated winding manner; and stator magnets arranged near the respective openings of the plurality of stator slots, a first rotor having a plurality of pole pieces and disposed coaxially with the stator to face the stator magnets; and a second rotor having a plurality of permanent magnets and disposed coaxially with the first rotor to face the first rotor, wherein the circumferential width of stator teeth positioned between the adjacent two of the stator magnets is narrower than the circumferential width of the stator slots.

IPC Classes  ?

• H02K 1/16 - Stator cores with slots for windings
• H02K 1/17 - Stator cores with permanent magnets
• H02K 16/02 - Machines with one stator and two rotors

Abstract

A welding inspection method includes a step S102 of removing an impurity at a surface of a weld with a surface treatment apparatus, a step S110 of irradiating the surface of the weld from which the impurity has been removed with transmission laser light, a step S120 of detecting reflected ultrasound reflected by a lower surface of a base material, and a step S150 of determining whether or not there is an internal defect in the weld based on a result of detection of reflected ultrasound.

IPC Classes  ?

• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
• B23K 31/12 - Processes relevant to this subclass, specially adapted for particular articles or purposes, but not covered by any single one of main groups relating to investigating the properties, e.g. the weldability, of materials
• G01N 33/2045 - Defects
• G01N 33/207 - Welded or soldered jointsSolderability

Abstract

An additive manufacturing apparatus includes: a chamber; a gas supply device that supplies an ambient gas into the chamber; an irradiation device that irradiates a molding region with an energy beam in order to mold a three dimensional molding object, the molding region being provided with a powder bed fusion on which a powder is spread in the chamber; and a controller that performs control related to additive manufacturing of the molding object, wherein the controller is configured to increase a pressure of the ambient gas in the chamber to be higher than an atmospheric pressure when the molding object is molded.

IPC Classes  ?

• B22F 10/322 - Process control of the atmosphere, e.g. composition or pressure in a building chamber of the gas flow, e.g. rate or direction
• B22F 10/28 - Powder bed fusion, e.g. selective laser melting [SLM] or electron beam melting [EBM]
• B22F 12/70 - Gas flow means
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 30/00 - Apparatus for additive manufacturingDetails thereof or accessories therefor
• B33Y 50/02 - Data acquisition or data processing for additive manufacturing for controlling or regulating additive manufacturing processes

Abstract

This boron compound is represented by formula (1). In formula (1), X1and X2are each independently selected from among electron-withdrawing groups, Y1and Y2are each independently selected from among hydrogen and electron-donating groups, with hydrogen not being selected for both simultaneously, R1 is selected from among C1-24 organic groups, the C1-24 organic group may have a substituent, and n is selected from among the integers from 0 to 2.

IPC Classes  ?

• C07F 5/02 - Boron compounds
• B01J 31/22 - Organic complexes
• C07B 31/00 - Reduction in general
• C07B 37/02 - Addition
• C07B 37/12 - Diels-Alder reactions
• C07B 61/00 - Other general methods
• C07D 215/06 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom

Abstract

In a method for creating isotope distribution data, samples for analysis having different concentrations of metabolites are prepared as samples containing metabolites of cells cultured in a medium containing a substrate labeled with a stable isotope, mass spectrometry is performed on each under the same analysis condition, mass spectrum data is analyzed for each to identify the type of the metabolites, and there are determined the number of metabolites included in a metabolite group made of unlabeled metabolites and/or isotopic isomers, and the signal intensities of mass peaks corresponding to all isotope isomers included in the metabolite group. The number of metabolites corresponding to all types of metabolites and the signal intensity are compared among the samples to select a sample for analysis for obtaining the isotope distribution, and data on the isotope distribution of the metabolite is integrated to create the isotope distribution data of the metabolite.

IPC Classes  ?

• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

A method for separating components using a supercritical fluid chromatograph, including: injecting a sample into a mobile phase containing a supercritical fluid and a modifier to introduce the sample into a column; and separating components in the sample during passing through the column; wherein the sample contains an oligonucleotide as a target component; the supercritical fluid contains carbon dioxide; and the modifier contains a solution containing at least one selected from the group consisting of ammonium, an alkylamine, and an amino alcohol, and an acid.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• B01D 15/40 - Selective adsorption, e.g. chromatography characterised by the separation mechanism using supercritical fluid as mobile phase or eluent